Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effect of LY3457263 compared with placebo on hemoglobin A1c HbA1c levels in adults with type 2 diabetes who have not reached their HbA1c goals despite stable treatment with semaglutide or tirzepatide. This phase 2, double-blind study aims to better understand how LY3457263 impacts blood sugar control in this population. Participants will receive once-weekly subcutaneous injections of either LY3457263 at one of three doses or a placebo, while continuing their stable dose of semaglutide or tirzepatide. The treatment period lasts 24 weeks, during which participants blood sugar and body weight changes will be monitored. The study includes a randomized, parallel-group design comparing these interventions. During the approximately 9-month study, participants will undergo assessments including measurements of HbA1c, fasting serum glucose, and body weight at baseline and week 24. Researchers will monitor safety and treatment effects throughout the study. Participants will have scheduled visits for treatment administration and evaluation, with the primary focus on HbA1c change from baseline at 24 weeks.
Actively Recruiting
Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.
Actively Recruiting
Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a Phase 2b study to evaluate the safety, immune response, and effectiveness of a new bivalent protein vaccine against Respiratory Syncytial Virus RSV and Human Metapneumovirus HMPV in adults aged 60 years and older. This randomized, placebo-controlled, observer-blind trial aims to prevent lower respiratory tract diseases caused by these viruses in an elderly population. The study is sponsored by Sanofi and focuses on vaccine prevention in healthy volunteers. Participants will receive a single intramuscular injection of either the bivalent RSVHMPV protein vaccine or a matching placebo. The study includes an initial Safety Lead-in Cohort of 200 participants randomized 11 to vaccine or placebo, followed by a Main Cohort of 7,800 participants also randomized 11 after safety review. Both groups receive only one dose and are monitored over time to assess vaccine effects and safety. Throughout the study, participants will be monitored for respiratory infections caused by RSV and HMPV from 14 days up to 12 months after vaccination. Researchers will also evaluate immune responses by measuring antibody levels before vaccination and at multiple time points afterward. Safety assessments include tracking adverse events immediately after vaccination and for up to one year. The total participation duration spans about 12 months, covering vaccination, follow-up visits, and safety monitoring.
Actively Recruiting
Researchers are evaluating a new blood test called Avantect to see if it can detect pancreatic cancer early in people aged 50 to 84 who have recently been diagnosed with type 2 diabetes or have elevated blood sugar levels. Pancreatic cancer is very deadly because it is often found too late for surgery, so early detection could improve treatment options. This trial aims to find out if Avantect can identify pancreatic cancer signals before symptoms appear. Participants will have their blood tested using the Avantect device at three scheduled visits over one year. If the test detects pancreatic cancer markers, participants and their doctors will be informed to arrange further imaging scans like MRI or CT to confirm the diagnosis. The study will track participants remotely for three years after consent to monitor any pancreatic cancer diagnosis or mortality through health registries. During the study, participants will provide blood samples and complete anxiety questionnaires at each visit. Researchers will assess the tests accuracy by measuring its sensitivity and specificity after three years. They will also evaluate how well the test predicts cancer presence, the stage of detected cancers, and surgery rates. The study offers free diagnostic testing and includes ongoing safety and health monitoring for all participants.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of two different oral doses of vapendavir compared to a placebo to find the right dose for reducing the severity and duration of respiratory symptoms caused by rhinovirus infections in people with chronic obstructive pulmonary disease COPD. This phase 2 clinical trial involves adult participants aged 40 to 85 years who have a confirmed COPD diagnosis and recent history of acute exacerbations. Participants will be randomly assigned to one of three groups one receiving 1000 mg of vapendavir, another receiving 500 mg of vapendavir, and the third receiving a placebo. The first dose is taken at the study site with food, followed by doses at home once daily with food for a total of seven doses. The study is double-blind, meaning neither participants nor researchers know who receives which treatment. Throughout the study, participants will complete daily evaluations of respiratory symptoms and severity using patient-reported outcome tools, including the Evaluating Respiratory Symptoms E-RS and Patient Global Impression of Severity PGIS scales. Lung function tests and oscillometry measurements will be conducted at multiple time points up to 42 days. The study aims to measure changes in respiratory symptoms and lung function to assess treatment impact and safety. Participation lasts for up to 12 weeks including baseline, treatment, and follow-up periods.